CAMBRIDGE

Cambridge University Press
978-1-107-03109-8 — Magnetic Nanoparticles in Biosensing and Medicine
Edited by Nicholas J. Darton , Adrian Ionescu , Justin Llandro
Index
More Information

Index

AC susceptibility
  magnetic measurements, 40–41
  Néel–Brown equation, 40–41
acoustic tweezers, 108–9
  standing acoustic wave (SAW) based acoustic tweezers, 108–9
  two-dimensional particle and cell delivery, 109
active drug targeting, magnetic drug delivery, 112–15
aggregation of nanoparticles
  Kendall growth law, 163–64
  nanoparticle capture, 163–64
alcohols tests, quantification, 87–88
aldehydes/tosyl
  epoxides, 84–85
  MNPs functionalization, 84–85
Ampère's law, atomic magnetic moments, 3
anisotropic magnetoresistance (AMR), 184–85
  detectivity limits, 204
  sensor properties, 183–84
antibodies, magnetic drug delivery, 118–20
antiferromagnetism, 12–16, 18–19, *see also* ferromagnetism
aptamers, magnetic drug delivery, 118–20
aqueous co-precipitation routes
  Massart method, 54–55
  MNPs synthesis, 54–55
Arrott plots
  Curie–Weiss law, 35–36
  magnetic measurements, 35–36
  temperature dependence of magnetization, 35–36
atomic magnetic moments, 3–7
  Ampère's law, 3
  Bohr magneton, 3, 4–6
  Hund's rules, 4–6
  Landé *g*-factor, 3–4
  Pauli exclusion principle, 4–5
  quantum mechanical wavefunction of two identical fermions, 4–5
  quenching of the orbital angular momentum, 5–6
  Russell–Saunders coupling, 4
  total atomic moment, 4
atomic susceptibilities calculation, 9–16
  antiferromagnetism, 12–16
  diamagnetism, 9–10
  ferromagnetism, 12–16
  paramagnetism, 11
axial magneto-aerotaxis, magnetosomes, 258–60

Beer's law, spectrophotometry, 87
Bingham fluid model, fluid and fluid flow, 154
biocompatibility of MNCs for use in vivo, 116–18
  cell toxicity, 118
  magnetic drug delivery, 116–18
  positron emission tomography (PET), 117
  single photon emission computed tomography (SPECT), 117
  surface coating, MNCs, 117–18
biological molecules attachment, magnetosomes, 268
biomineralization of magnetosomes, 262–64
biosorbents for heavy metals, magnetotactic bacteria, 267
Bloch domain walls, 20–22
Bloch T3/2 law
  magnetic measurements, 31–32
  spontaneous magnetization, 31–32
Bloch wave, 8
Bohr magneton, atomic magnetic moments, 3, 4–6
Bohr radius, diamagnetism, 10
Brillouin function, ferromagnetism, 12–13
Brillouin zone, 8
Brownian relaxation, magnetization of nanoparticles, 30

camptothecin, magnetic drug targeting, 127–28
capture of nanoparticles, *see* nanoparticle capture
carbodiimides
  epoxides, 81
  linker molecules, 81
  self-assembled monolayers (SAMs), 72
Casson model, fluid and fluid flow, 155
catalytic tweezers, 104–8
  applications, 107–8
  performance improvement, 106

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-03109-8 — Magnetic Nanoparticles in Biosensing and Medicine
Edited by Nicholas J. Darton , Adrian Ionescu , Justin Llandro
Index
More Information

cell separation, magnetosomes, 268
cell sorting and separation, magnetotactic bacteria, 267
cell toxicity
  biocompatibility of MNCs for use in vivo, 118
  magnetic drug delivery, 118
changes in the physical properties of materials, nanometer scale, 1
Clausius–Mossotti factor
  electric tweezers, 100–2
  rotating nanowires, 100–2
clustered magnetic nanoparticles, MR relaxivity, 240–43
coating effect, 244–45, *see also* gold-coated particles
  MR relaxivity of MNPs, 236–37
collection of magnetic moments, crystals, 8
contrast agents
  gadolinium complexes, 233
  magnetic resonance imaging (MRI), 228–29, 233, 246
  MNPs for MRI contrast agents, 228–29
  relaxation, MRI contrast agents, 233
  types, 233
co-precipitation, MNPs synthesis, 115–16
critical exponents of phase transitions, magnetic measurements, 38–40
crystals, collection of magnetic moments, 8
Curie–Weiss law
  Arrott plots, 35–36
  ferromagnetism, 12–13
  magnetic measurements, 35–36
  temperature dependence of magnetization, 35–36

de Broglie wavelength of the electron, 1
detecting MNRs
  configurations, MR sensors, 195–96
  detectivity limits, 201–4
  fringe fields, 195–96
  magnetoresistive (MR) sensors, 195–201
  principle, MR sensors, 195–96
detectivity limits
  anisotropic magnetoresistance (AMR), 204
  giant magnetoresistance (GMR), 204
  magnetoresistive (MR) sensors, 201–4
  non-white noise, 203–4
  sensor noise, 201–4
  shot noise, 202–3
  spin valves (SV), 204
  thermal noise, 202–3
  tunnel magnetoresistance (TMR), 204
  white noises, 202–3
diamagnetism, 9–10
  atomic susceptibilities calculation, 9–10
  Bohr radius, 10
  diamagnetic susceptibility of some materials around 293 K, 11t1.4
  examples of diamagnets, 10
  Landau diamagnetism, 10
  Landau susceptibility, 10
  Larmor diamagnetism, 9, 10
  Lenz's law, 9
  sources of diamagnetism, 10
dipole magnets, magnetic drug targeting, 124
doxorubicin, magnetic drug targeting, 127–28
drug targeting, *see* magnetic drug delivery; magnetic drug targeting

eigenstates, 2
electric tweezers, 96–103
  applications, 99–103
  Clausius–Mossotti factor, 100–2
  rotating nanowires, 98–103
  transporting nanocapsules, 102–3
  transporting nanowires, 96–98, 99
electrochemical deposition
  gold-coated particles, 76–78
  photolithography, 76–78
electrochemical potential for electrons (Fermi level), 1
enzyme immobilization, magnetosomes, 268
epichlorohydrin, epoxides, 79–80
epoxides, 79–85
  aldehydes/tosyl, 84–85
  carbodiimides, 81
  epichlorohydrin, 79–80
  ethanolamine, 79
  linker molecules, 81–83
  MNPs functionalization, 79–85
  organic vs. aqueous, 80–81
  spacer molecules, 84
  SU8 epoxy resin, 79
  tosyl/aldehydes, 84–85
ESIONs (extremely small iron oxide nanoparticles), MR relaxivity of MNPs, 238, 246
ethanolamine, epoxides, 79
exchange (bias) anisotropy, 18–19
externally applied magnetic field
  aggregation of nanoparticles, 163–64
  nanoparticle capture, 160–64
  nature of, 160–63
extremely small iron oxide nanoparticles (ESIONs), MR relaxivity of MNPs, 238, 246

Fehling's test (for aldehydes), quantification, 87
Fermi function, paramagnetism, 11
Fermi level (electrochemical potential for electrons), 1
ferrimagnetic iron oxide nanoparticles (FIONs), MR relaxivity of MNPs, 236–37, 246
ferrite nanoparticles, composition effects, MR relaxivity of MNPs, 238
ferromagnetic nanoparticles, MR relaxivity, 239–40

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-03109-8 — Magnetic Nanoparticles in Biosensing and Medicine
Edited by Nicholas J. Darton , Adrian Ionescu , Justin Llandro
Index
More Information

ferromagnetism, 12–16
  atomic susceptibilities calculation, 12–16
  Brillouin function, 12–13
  Curie–Weiss law, 12–13
  exchange interactions, 13–15
  Hamiltonian of the system, 13–14
  Heisenberg exchange mechanism, 13–14
  magnons, 15–16
  Ruderman–Kittel–Kasuya–Yosida (RKKY) model, 15
  Stoner criterion, 14–15
  susceptibility of local moments, 12–13
  Weiss molecular field, 12–13
  Zeeman energy, 12–13
field dependence of the order parameter along the critical isotherm, magnetic measurements, 37
FIONs (ferrimagnetic iron oxide nanoparticles), MR relaxivity of MNPs, 236–37, 246
fluid and fluid flow
  Bingham fluid model, 154
  Casson model, 155
  Herschel–Bulkley fluid model, 154, 155
  mammalian vasculature, 155–56
  nanoparticle capture, 152–56
  Navier–Stokes equations, 155–56
  Newtonian fluid behavior, 152–56
fluorescence quenching/enhancement, gold-coated particles, 76
force balance, MNPs modeling, 158–60
fringe fields, detecting MNRs, 195–96
Fullprof profile refinement program, structural analysis, 46
functionalization of MNCs for in vivo drug targeting, 118–20
future directions of research, 270–71

gadolinium complexes, magnetic resonance imaging (MRI), 233
gas and solid routes
  laser pyrolysis of carbonyl precursors, 61–62
  MNPs synthesis, 61–62
genomics of magnetotactic bacteria, 260–61
giant magnetoimpedance (GMI)
  biosensor prototypes, 214–18
  magnetic fields present, 215
  sensing of living systems, 218
  sensor sensitivity, 211–12
  sensors in microfluidic systems, 219–20
giant magnetoresistance (GMR), 186–88
  detectivity limits, 204
  sensor properties, 183–84
  spin valves (SV), 187–88
GMI, *see* giant magnetoimpedance
GMR, *see* giant magnetoresistance
gold/SU8 microcarrier, MNPs functionalization, 88
gold-coated particles, 68–79, *see also* coating effect
  alternative directions, 78–79
  chemical suppliers, 76
  electrochemical deposition, 76–78
  fluorescence quenching/enhancement, 76
  mixed SAMs, 73–75
  MNPs functionalization, 68–79
  photolithography, 76–78
  SAM monomers, 70–73
  self-assembled monolayers (SAMs), 68–75
growth under confinement
  MNPs synthesis, 57–58
  reverse microemulsions, 57–58

Halbach arrays, magnetic drug targeting, 124–25
Hall effect, 172–77
  discovery, 172
  quantifying the Hall effect, 173–74
Hall effect biosensors, 179–81
  compound semiconductors, 179
  integrated current lines for rapid detection, 179–81
  MNPs detection for medical diagnostics, 179–81
  silicon-based bio-Hall sensors, 179
Hall effect sensors
  advantages, 177
  applications, 172–73
  design considerations, 176–77
  material selection, 174–76
  sensitivity, 174–76
  sensor arrangements, 177
  thermal stability, 176–77
Hamiltonian of the system, ferromagnetism, 13–14
Hartree–Fock approximation, paramagnetism, 11
Hartree–Fock method, 3
Heisenberg exchange mechanism, ferromagnetism, 13–14
Herschel–Bulkley fluid model, fluid and fluid flow, 154, 155
high gradient magnetic separation (HGMS), magnetic drug targeting, 122, 125
hot organic solvents, MNPs synthesis, 55–57
Hund's rules
  atomic magnetic moments, 4–6
  calculation, 46
hydrodynamic size, magnetic nanoparticles (MNPs), 53
hydrogels, MNPs synthesis, 59–60
hydrothermal synthesis, MNPs synthesis, 116
hyperthermia, magnetic, magnetic drug targeting, 125–26, 269

inorganic matrices
  MNPs synthesis, 60–61
  Stöber method, 60
iron oxides, magnetic nanoparticles (MNPs), 52–53

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-03109-8 — Magnetic Nanoparticles in Biosensing and Medicine
Edited by Nicholas J. Darton , Adrian Ionescu , Justin Llandro
Index
More Information

Kaiser test (for primary amines), quantification, 86–87
Kendall growth law, aggregation of nanoparticles, 163–64
Kretschmann–Raether configuration, plasmonic micro-trapping, 111

Landau diamagnetism, 10
Landau susceptibility, 10
Landau theory, magnetic measurements, 35–36
Landau–Lifshitz–Gilbert (LLG) equation, magnetization reversal, 25–26
Landé *g*-factor, atomic magnetic moments, 3–4
Langevin equation
  magnetization of nanoparticles, 27, 30
  superparamagnets analysis, 12
Larmor (molar) diamagnetic susceptibility, calculation, 47
Larmor diamagnetism, 9, 10
laser pyrolysis of carbonyl precursors, MNPs synthesis, 61–62, 116
Lenz's law, diamagnetism, 9
linker molecules, 81–83
  carbodiimides, 81
  cyclisation, 82–83
  electrophiles, 81–83
  epoxides, 81–83
  homo-bifunctional linkers, 81
  MNPs functionalization, 81–83
  nucleophiles, 81–83
liposomes, MNPs synthesis, 58–59
loading level, MNPs functionalization, 88
localized surface plasmon (LSP), plasmon nano-optical tweezers, 109–10

macroscopic considerations, 7–8
magnetic antibodies, magnetosomes, 268
magnetic domains, 19–26
  Bloch domain walls, 20–22
  classification, 20
  domain walls, 20–22
  magnetization reversal, 22–26
  Néel domain walls, 20–22
  neutron scattering, 20
magnetic drug delivery, 112–34
  active drug targeting, 112–15
  antibodies, 118–20
  aptamers, 118–20
  biocompatibility of MNCs for use in vivo, 116–18
  cell toxicity, 118
  functionalization of MNCs for in vivo drug targeting, 118–20
  magnetic drug targeting, 120–34
  MNPs as the base unit, 115–16
  MNPs synthesis, 115–16
  passive drug targeting, 112–15
  peptides, 118–20
  positron emission tomography (PET), 117
  single photon emission computed tomography (SPECT), 117
  surface coating, MNCs, 117–18
  virus-MNP hybrids, 120
magnetic drug targeting, 120–34
  camptothecin, 127–28
  dipole magnets, 124
  doxorubicin, 127–28
  forces, 121–25
  Halbach arrays, 124–25
  high gradient magnetic separation (HGMS), 122, 125
  hyperthermia, magnetic, 269
  magnetic hyperthermia, 125–26
  magnetic induced therapy, 132
  magnetic resonance imaging (MRI), 132–34
  magnetically induced drug release, 128
  magnetofection, 132
  methotrexate–MNP conjugates, 127–28
  Niobe® Stereotaxis System, 124–25
  paclitaxel, 127–28
  studies, 127–28, 134
  thermoablation, 125–26, 269
magnetic force for transporting nanoparticles, magnetic tweezers, 94
magnetic hyperthermia, magnetic drug targeting, 125–26
magnetic induced therapy, magnetic drug targeting, 132
magnetic measurements, 30–44
  AC susceptibility, 40–41
  Arrott plots, 35–36
  Bloch T3/2 law, 31–32
  critical exponents of phase transitions, 38–40
  critical phenomena, 36–40
  Curie–Weiss law, 35–36
  field dependence of the order parameter along the critical isotherm, 37
  Landau theory, 35–36
  magnetocaloric effect, 32–34
  magnetometers, 30–31
  Mössbauer spectroscopy, 41–42
  neutron scattering, 37–40, 42–44
  specific heat, 37
  spin density fluctuations close to *Tc*, thermal variation, 37–40
  spontaneous magnetization, 31–32
  temperature dependence of magnetization, 31–36
  thermal dependence of the initial susceptibility, 37
  thermal dependence of the order parameter, 36–37
  X-ray magnetic circular dichroism (XMCD), 44

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-03109-8 — Magnetic Nanoparticles in Biosensing and Medicine
Edited by Nicholas J. Darton , Adrian Ionescu , Justin Llandro
Index
More Information

magnetic nanoparticles (MNPs)
force balance, 158–60
hydrodynamic size, 53
iron oxides, 52–53
medical applications, 269
MNPs for MRI contrast agents, 228–29
nature of, 156–60
properties re MRI, 234–36
synthesis, *see* synthesis of MNPs
toxicity, 245–46
magnetic relaxation switch (MRS), MR relaxivity of MNPs, 241
magnetic resonance imaging (MRI), *see also* MR relaxivity of MNPs
contrast agents, 228–29, 233, 246
detection, 230–31
gadolinium complexes, 233
magnetic drug targeting, 132–34
MNPs properties, 234–36
potentials, 230
principles, 228–29
proton alignment, 230
relaxation, 231–32
relaxation, MRI contrast agents, 233
spatial information, 232
magnetic tweezers, 94–96
magnetic force for transporting nanoparticles, 94
rotating nanowires, 94–96
unique applications, 94
Magnetically Induced Drug Release, magnetic drug targeting, 128
magnetization of nanoparticles, 26–30
Brownian relaxation, 30
Langevin equation, 12, 27, 30
Néel relaxation time, 27
Stern–Gerlach type experiment, 28
superparamagnetic relaxation, 30
magnetization processes, 16–30
exchange (bias) anisotropy, 18–19
magnetic anisotropies, 16–19
magnetic domains, 19–26
magnetization of nanoparticles, 26–30
magneto-crystalline anisotropy constants, 17t1.6
magneto-elastic anisotropy, 18
magnetization reversal
Landau–Lifshitz–Gilbert (LLG) equation, 25–26
magnetic domains, 22–26
magnetization dynamics, 24–26
Néel relaxation time, 24–26
Néel–Brown equation, 24–26
thin films and particles, 22–24
magneto-aerotaxis, magnetosomes, 257–60
magnetocaloric effect
magnetic measurements, 32–34
temperature dependence of magnetization, 32–34
magneto-crystalline anisotropy constants, 17t1.6
magneto-elastic anisotropy, 18
magnetofection, magnetic drug targeting, 132
magnetoimpedance, 208–11
magnetoimpedance biosensors, 206–20
development, 206–8
GMI biosensor prototypes, 214–18
GMI sensing of living systems, 218
GMI sensor sensitivity, 211–12
GMI sensors in microfluidic systems, 219–20
magnetism related sensing steps, 207–8
magnetoimpedance, 208–11
MNPs synthesis, 212–13
magnetometers, 30–31
magneto-optical Kerr effect (MOKE), 30–31
superconducting quantum interference device (SQUID), 30–31
magneto-optical Kerr effect (MOKE), magnetometers, 30–31
magnetoresistive (MR) sensors, 181–201
advantages, 205–6
anisotropic magnetoresistance (AMR), 183–85
applications, 205–6
competing technologies, 205–6
configurations, 195–96
detecting MNRs, 195–201
detectivity limits, 201–4
fringe fields, 195–96
giant magnetoresistance (GMR), 183–84, 186–88
non-white noise, 203–4
principle, 195–96
sensor noise, 201–4
shot noise, 202–3
technological development, 205–6
thermal noise, 202–3
tunnel magnetoresistance (TMR), 183–84, 189–92
types, 183–84
white noises, 202–3
magnetoresistive effect, 181–92
magnetoresistive sensor linearization, 192–95
Stoner–Wohlfarth model, 194
magnetosomes, 251, *see also* magnetotactic bacteria
applications, 267–70
arrangement, 255–57
axial magneto-aerotaxis, 258–60
biological molecules attachment, 268
biomineralization, 262–64
cell separation, 268
composition, 255–57
enzyme immobilization, 268
function, 257–60
magnetic antibodies, 268
magneto-aerotaxis, 257–60
magnetotaxis, 257–60
morphology, 255–57
nanobodies, 269
nucleic acids isolation, 269
polar magneto-aerotaxis, 258–60

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-03109-8 — Magnetic Nanoparticles in Biosensing and Medicine
Edited by Nicholas J. Darton , Adrian Ionescu , Justin Llandro
Index
More Information

magnetosomes (*cont.*)
proteins applications, 268–69
purification, 265–66
size, 255–57
toxicity, 270
Magnetospirillum spp.
biomineralization of magnetosomes, 262–64
magnetosomes purification, 265–66
mass culture, 265–66
magnetotactic bacteria, 251–71, *see also* magnetosomes
applications, 267–70
biosorbents for heavy metals, 267
cell sorting and separation, 267
defined, 251
distribution, 253–54
diversity, 251, 252–55
genomics, 260–61
mass culture, 265–66
meteorites/rocks magnetic poles determination, 267
micro-robots applications, 267
nitrogen fixation, 254–55
phylogeny, 252–55
physiology, 252–55
sulfur compounds metabolism, 254
toxicity, 270
magnetotaxis, magnetosomes, 257–60
magnons, ferromagnetism, 15–16
mammalian vasculature, fluid and fluid flow, 155–56
manipulation, *see* magnetic drug delivery; tweezers
Massart method, MNPs synthesis, 54–55
Maxwell's equations, nanoparticle capture, 160–61
medical applications, MNPs, 269
medical diagnostics, Hall effect biosensors, MNPs detection, 179–81
mesoporous silica nanoparticle (MSN), MR relaxivity of MNPs, 242–43
metal-organic frameworks (MOFs), MNPs synthesis, 60
meteorites/rocks magnetic poles determination, magnetotactic bacteria, 267
methotrexate–MNP conjugates, magnetic drug targeting, 127–28
micelle microemulsion, MNPs synthesis, 116
micelles, MNPs synthesis, 58–59
micro-robots applications, magnetotactic bacteria, 267
MNPs, *see* magnetic nanoparticles
MOFs (metal-organic frameworks), MNPs synthesis, 60
Mössbauer spectroscopy
magnetic measurements, 41–42
superparamagnetic relaxation, 41–42
MR relaxivity of MNPs, 236–45
clustered MNPs, 240–43
coating effect, 243–45
control, 236–45
extremely small iron oxide nanoparticles (ESIONs), 238, 246
ferrimagnetic iron oxide nanoparticles (FIONs), 236–37
ferrite nanoparticles, composition effects, 238
ferromagnetic nanoparticles, 239–40
magnetic relaxation switch (MRS), 241
mesoporous silica nanoparticle (MSN), 242–43
size-dependent MR relaxivity, 236–38
MRI, *see* magnetic resonance imaging
MRS (magnetic relaxation switch), MR relaxivity of MNPs, 241
MSN (mesoporous silica nanoparticle), MR relaxivity of MNPs, 242–43

nanobodies, magnetosomes, 269
nanocapsules, transporting, electric tweezers, 102–3
nanocomposites from solution routes, MNPs synthesis, 58–61
nanogels, MNPs synthesis, 59–60
nanometer scale, changes in the physical properties of materials, 1
nanoparticle capture, 151–68
aggregates capture, 164–68
aggregation of nanoparticles, 163–64
capture angle approach, 164–66
capture of nanoparticles or nanoparticle aggregates, 164–68
externally applied magnetic field, 160–64
fluid and fluid flow, 152–56
Maxwell's equations, 160–61
MNPs modeling, 156–60
MNPs, nature of, 156–60
modeling considerations, 151
Newtonian fluid behavior, 152–56
partial capture, 166–68
physical mechanisms, 151–68
total capture, 166–68
nano-trapping with plasmonic antennas, tweezers, 111
nanowires, rotating
electric tweezers, 98–103
magnetic tweezers, 94–96
nanowires, transporting, electric tweezers, 96–98, 99
Navier–Stokes equations, fluid and fluid flow, 155–56
Néel domain walls, 20–22
Néel relaxation time
magnetization of nanoparticles, 27
magnetization reversal, 24–26

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-03109-8 — Magnetic Nanoparticles in Biosensing and Medicine
Edited by Nicholas J. Darton , Adrian Ionescu , Justin Llandro
Index
More Information

Néel–Brown equation
  AC susceptibility, 40–41
  magnetization reversal, 24–26
neutron scattering
  magnetic domains, 20
  magnetic measurements, 37–40, 42–44
Ninhydrin test (for primary amines), quantification, 86–87
Niobe® Stereotaxis System, magnetic drug targeting, 124–25
non-white noise
  detectivity limits, 203–4
  magnetoresistive (MR) sensors, 203–4
nucleic acids isolation, magnetosomes, 269
nucleic acids, RNA transcription, optical tweezers, 93

optical tweezers, 91–94
  advantages, 94
  Rayleigh particle gradient force, 91–92
  RNA transcription, 93
  scattering force, 92–93
optoelectronic tweezers, 103
organic matrices, MNPs synthesis, 58–60
  hydrogels, 59–60
  liposomes, 58–59
  metal-organic frameworks (MOFs), 60
  micelles, 58–59
  nanogels, 59–60
  polymer matrices, 58
  solid lipid nanoparticles, 59–60
organized surfactant assemblies, MNPs synthesis, 57–58

paclitaxel, magnetic drug targeting, 127–28
paramagnetism
  atomic susceptibilities calculation, 11
  Fermi function, 11
  Hartree–Fock approximation, 11
  paramagnetic susceptibility of some transition metals around 293 K, 11
  Zeeman splitting, 11
passive drug targeting, magnetic drug delivery, 112–15
Pauli exclusion principle, atomic magnetic moments, 4–5
peptides, magnetic drug delivery, 118–20
PET, *see* positron emission tomography
photoelectron emission microscopy (PEEM), structural analysis, 45
photolithography
  alternative directions, 78–79
  electrochemical deposition, 76–78
  gold-coated particles, 76–78
plasmon nano-optical tweezers, 109–10
  localized surface plasmon (LSP), 109–10
  surface plasmon polariton (SPP), 109–10
plasmonic micro-trapping, tweezers, 111
polar magneto-aerotaxis, magnetosomes, 258–60
polymer matrices, MNPs synthesis, 58
positron emission tomography (PET)
  biocompatibility of MNCs for use in vivo, 117
  magnetic drug delivery, 117
productivity (yield), MNPs synthesis, 63
proteins applications, magnetosomes, 268–69

quantification, 85–88
  alcohols tests, 87–88
  Fehling's test (for aldehydes), 87
  Kaiser test (for primary amines), 86–87
  MNPs functionalization, 85–88
  Ninhydrin test (for primary amines), 86–87
  spectrophotometry, 87
quantum mechanical concepts, 2–3
quantum mechanical wavefunction of two identical fermions, 4–5
quenching of the orbital angular momentum, atomic magnetic moments, 5–6

Rayleigh particle, gradient force, 91–92
relaxivity of MNPs, MR, *see* MR relaxivity of MNPs
research future directions, 270–71
reverse microemulsions, MNPs synthesis, 57–58
RNA transcription, optical tweezers, 93
rocks/meteorites magnetic poles determination, magnetotactic bacteria, 267
rotating nanowires
  electric tweezers, 98–103
  magnetic tweezers, 94–96
Ruderman–Kittel–Kasuya–Yosida (RKKY) model, ferromagnetism, 15
Russell–Saunders coupling, atomic magnetic moments, 4

SAMs, *see* self-assembled monolayers
SAW (standing acoustic wave) based acoustic tweezers, 108–9
Schrödinger equation, 2–3
self-assembled monolayers (SAMs)
  amines, 72
  biotin, 73
  carbodiimides, 72
  carboxylic acids, 72
  chain, 71
  chemical suppliers, 76
  gold-coated particles, 68–75
  head groups, 71–73
  hydroxyls, 71
  mixed SAMs, 73–75
  NHS esters, 73
  SAM monomers, 70–73
  tail groups, 70–71

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-03109-8 — Magnetic Nanoparticles in Biosensing and Medicine
Edited by Nicholas J. Darton , Adrian Ionescu , Justin Llandro
Index
More Information

self-induced back-action (SIBA) trapping, tweezers, 111–12
sensor noise, detectivity limits, 201–4
shot noise
  detectivity limits, 202–3
  magnetoresistive (MR) sensors, 202–3
SIBA (self-induced back-action) trapping, tweezers, 111–12
silicon-based bio-Hall sensors, 179
single photon emission computed tomography (SPECT)
  biocompatibility of MNCs for use in vivo, 117
  magnetic drug delivery, 117
solid lipid nanoparticles, MNPs synthesis, 59–60
solid routes, MNPs synthesis, 62
spacer molecules
  epoxides, 84
  MNPs functionalization, 84
specific heat, magnetic measurements, 37
SPECT, *see* single photon emission computed tomography
spectrophotometry
  Beer's law, 87
  quantification, 87
spin density fluctuations close to *Tc*, thermal variation, magnetic measurements, 37–40
spin valves (SV)
  detectivity limits, 204
  giant magnetoresistance (GMR), 187–88
spontaneous magnetization
  Bloch T3/2 law, 31–32
  magnetic measurements, 31–32
  temperature dependence of magnetization, 31–32
SPP (surface plasmon polariton), plasmon nano-optical tweezers, 109–10
standing acoustic wave (SAW) based acoustic tweezers, 108–9
Stern–Gerlach type experiment, magnetization of nanoparticles, 28
Stöber method, MNPs synthesis, 60
Stoner criterion, ferromagnetism, 14–15
Stoner–Wohlfarth model, magnetoresistive sensor linearization, 194
structural analysis, 45–46
  Fullprof profile refinement program, 46
  photoelectron emission microscopy (PEEM), 45
  transmission electron microscopy (TEM), 45
studies, magnetic drug targeting, 127–28, 134
SU8 epoxy resin, 79
  gold/SU8 microcarrier, 88
superconducting quantum interference device (SQUID), magnetometers, 30–31
superparamagnetic relaxation
  magnetization of nanoparticles, 30
  Mössbauer spectroscopy, 41–42
superparamagnetism, 30, 115
  bead array counter concept, 207
  superparamagnetic beads (SPBs), 179, 195–96, 219–20
  superparamagnetic behavior, 194–95
  superparamagnetic labels, 207–8
  superparamagnetic nanoparticles, 234–36
surface coating, MNCs, *see* gold-coated particles
  biocompatibility of MNCs for use in vivo, 117–18
  magnetic drug delivery, 117–18
surface plasmon polariton (SPP), plasmon nano-optical tweezers, 109–10
SV, *see* spin valves
synthesis of MNPs, 52–63, 115–16
  aqueous co-precipitation routes, 54–55
  co-precipitation, 115–16
  gas and solid routes, 61–62
  growth under confinement, 57–58
  hot organic solvents, 55–57
  hydrothermal synthesis, 116
  inorganic matrices, 60–61
  laser pyrolysis of carbonyl precursors, 61–62, 116
  magnetoimpedance biosensors, 212–13
  Massart method, 54–55
  micelle microemulsion, 116
  nanocomposites from solution routes, 58–61
  organic matrices, 58–60
  organized surfactant assemblies, 57–58
  particle aggregation prevention, 116
  reverse microemulsions, 57–58
  solid routes, 62
  Stöber method, 60
  *T*1 (positive) contrast agents, 61
  thermal decomposition, 116
  yield (productivity), 63

*T*1 ('positive') contrast agents, MNPs synthesis, 61
targeting, drug, *see* magnetic drug delivery; magnetic drug targeting
TEM (transmission electron microscopy), structural analysis, 45
temperature dependence of magnetization, 31–36
  Arrott plots, 35–36
  Curie–Weiss law, 35–36
  magnetocaloric effect, 32–34
  spontaneous magnetization, 31–32
thermal decomposition, MNPs synthesis, 116
thermal dependence of the initial susceptibility, magnetic measurements, 37
thermal dependence of the order parameter, magnetic measurements, 36–37
thermal noise
  detectivity limits, 202–3
  magnetoresistive (MR) sensors, 202–3

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-03109-8 — Magnetic Nanoparticles in Biosensing and Medicine
Edited by Nicholas J. Darton , Adrian Ionescu , Justin Llandro
Index
More Information

thermoablation, magnetic drug targeting, 125–26, 269
TMR, *see* tunnel magnetoresistance
tosyl/aldehydes
  epoxides, 84–85
  MNPs functionalization, 84–85
toxicity
  cell toxicity, biocompatibility of MNCs for use in vivo, 118
  magnetic nanoparticles (MNPs), 245–46
  magnetosomes, 270
  magnetotactic bacteria, 270
transmission electron microscopy (TEM), structural analysis, 45
transporting nanocapsules, electric tweezers, 102–3
transporting nanowires, electric tweezers, 96–98, 99
tunnel magnetoresistance (TMR), 189–92
  detectivity limits, 204
  sensor properties, 183–84
tweezers, 91–112
  acoustic tweezers, 108–9
  catalytic tweezers, 104–8
  electric tweezers, 96–103
  magnetic tweezers, 94–96
  nano-trapping with plasmonic antennas, 111
  optical tweezers, 91–94
  optoelectronic tweezers, 103
  plasmon nano-optical tweezers, 109–10
  plasmonic micro-trapping, 111
  self-induced back-action (SIBA) trapping, 111–12
two-dimensional particle and cell delivery, acoustic tweezers, 109

ultrasmall superparamagnetic iron oxide nanoparticles (USPIO), MR relaxivity of MNPs, 238

virus-MNP hybrids, magnetic drug delivery, 120

Weiss molecular field, ferromagnetism, 12–13
white noises
  detectivity limits, 202–3
  magnetoresistive (MR) sensors, 202–3
  shot noise, 202–3
  thermal noise, 202–3

X-ray magnetic circular dichroism (XMCD), magnetic measurements, 44

yield (productivity), MNPs synthesis, 63

Zeeman energy, ferromagnetism, 12–13
Zeeman splitting
  Mössbauer spectroscopy, 41–42
  paramagnetism, 11

© in this web service Cambridge University Press www.cambridge.org